{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:42Z","timestamp":1792788222202,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Erlangen","id":[{"id":"https:\/\/ror.org\/0030f2a11","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Human herpesvirus infections cover a wide range of pathogenic outcomes and challenging situations in the medical field. All herpesviral \u03b1-, \u03b2-, and\n                    <jats:inline-formula>\n                      <jats:tex-math>$$\\gamma$$<\/jats:tex-math>\n                    <\/jats:inline-formula>\n                    -subfamilies comprise representatives with a huge clinical impact on human health. The basic and translational research efforts are strongly directed towards the improved molecular understanding of infections and development of novel antiviral test systems and preventive measures. We utilized cell culture-based quantitative models for the assessment of antiviral prototype drugs against human and animal pathogenic herpesviruses. Our analysis focused on approved, developmental, and experimental compounds. All three investigated herpesviruses showed sensitivity against the selected antivirals. The single-drug antiviral treatments identified mean effective concentrations in the micromolar range, for abemaciclib (ABE) and the pharmacophore compound 020 (P-020), as well as submicromolar to nanomolar range, for brincidofovir (BCV) and cyclin-dependent kinase inhibitor of CDK7 (LDC4297). Time-of-addition experiments addressed questions of temporal potency of inhibition and effects on the expression of individual viral proteins. The results demonstrated that these drugs were mostly robust and did generally show moderate or no difference in antiviral activity when administered pre-, post-, or total duration-infection. By addressing the question of potential drug\u2013drug synergies in combinatorial cotreatment settings, we identified effective conditions of combined antiherpesviral drug treatment (cAHT), such as ABE + LDC4297, as demonstrated for all three viruses. Thus, the study provides new information about antiherpesviral potency and characteristics of a selection of four antiviral prototype inhibitors. Especially, examples of broadness in synergistic combination treatment suggested options to improve antiherpesviral therapy strategies.\n                  <\/jats:p>","DOI":"10.1186\/s12985-026-03303-1","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:12:46Z","timestamp":1790050366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessment of combined antiviral drug treatment against selected \u03b1-, \u03b2-, and \u03b3-herpesviruses"],"prefix":"10.1186","volume":"23","author":[{"given":"Lucio","family":"Fortelny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Obergf\u00e4ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishore","family":"Dhotre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tillmanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"6","key":"3303_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens15060631","volume":"15","author":"L Fortelny","year":"2026","unstructured":"Fortelny L, Marschall M. The current status of Herpesviridae as major human pathogens: a 10-year diagnostic evaluation in Germany. Pathogens. 2026;15(6):631.","journal-title":"Pathogens"},{"issue":"1","key":"3303_CR2","doi-asserted-by":"publisher","first-page":"2425744","DOI":"10.1080\/21505594.2024.2425744","volume":"15","author":"S Dan","year":"2024","unstructured":"Dan S, Liping H, Chengyu S, Yaoxin L, Shaoju Q, Zhiwei F, et al. An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application. Virulence. 2024;15(1):2425744.","journal-title":"Virulence"},{"key":"3303_CR3","doi-asserted-by":"crossref","unstructured":"Goodrum F, Caviness K, Zagallo P. Human cytomegalovirus persistence. Cellular microbiology. 2012;14(5).","DOI":"10.1111\/j.1462-5822.2012.01774.x"},{"key":"3303_CR4","unstructured":"Gewurz B, Longnecker R, Cohen J. Epstein-barr virus. Fields Virology. 2021;2(7)."},{"key":"3303_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.2007.00586.x","author":"PG Arduino","year":"2008","unstructured":"Arduino PG, Porter S. Herpes simplex virus type 1 infection: overview on relevant clinico-pathological features. J Oral Pathol Med. 2008. https:\/\/doi.org\/10.1111\/j.1600-0714.2007.00586.x.","journal-title":"J Oral Pathol Med"},{"key":"3303_CR6","doi-asserted-by":"crossref","unstructured":"Wei L, Chen SJ, Huang SF, Chan YJ, Wang FD, Chen HP. Clinical significance of human cytomegalovirus viruria and the effect of antiviral therapy in hematopoietic stem cell transplant recipients. Journal of microbiology, immunology, and infection. 2019;52(3).","DOI":"10.1016\/j.jmii.2017.08.019"},{"issue":"4","key":"3303_CR7","volume":"114","author":"H Buxmann","year":"2017","unstructured":"Buxmann H, Hamprecht K, Meyer-Wittkopf M, Friese K. Primary human cytomegalovirus (HCMV) infection in pregnancy. Dtsch Arztebl Int. 2017;114(4):45.","journal-title":"Dtsch Arztebl Int"},{"key":"3303_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008173430707","author":"J Cohen","year":"2000","unstructured":"Cohen J. Epstein-Barr virus infection. N Engl J Med. 2000. https:\/\/doi.org\/10.1056\/NEJM200008173430707.","journal-title":"N Engl J Med"},{"key":"3303_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed7120439","author":"SJ Chen","year":"2022","unstructured":"Chen SJ, Wang SC, Chen YC. Challenges, recent advances and perspectives in the treatment of human cytomegalovirus infections. Trop Med Infect Dis. 2022. https:\/\/doi.org\/10.3390\/tropicalmed7120439.","journal-title":"Trop Med Infect Dis"},{"key":"3303_CR10","volume-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","author":"DW Kimberlin","year":"2007","unstructured":"Kimberlin DW, Whitley RJ. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press; 2007."},{"key":"3303_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","volume":"159","author":"WJ Britt","year":"2018","unstructured":"Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antivir Res. 2018;159:153\u201374.","journal-title":"Antivir Res"},{"key":"3303_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24050997","author":"G Andrei","year":"2019","unstructured":"Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein\u207bBarr virus. Molecules. 2019. https:\/\/doi.org\/10.3390\/molecules24050997.","journal-title":"Molecules"},{"key":"3303_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105689","author":"GV Syrigos","year":"2023","unstructured":"Syrigos GV, Feige M, Dirlam A, Businger R, Gruska I, Wiebusch L, et al. Abemaciclib restricts HCMV replication by suppressing pUL97-mediated phosphorylation of SAMHD1. Antivir Res. 2023. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105689.","journal-title":"Antivir Res"},{"key":"3303_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122680","author":"M Wild","year":"2023","unstructured":"Wild M, Karner D, Eickhoff J, Wagner S, Kicuntod J, Chang W, et al. Combined treatment with host-directed and anticytomegaloviral kinase inhibitors: mechanisms, synergisms and drug resistance barriers. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15122680.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3303_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020575","volume":"22","author":"M Wild","year":"2021","unstructured":"Wild M, Kicuntod J, Seyler L, Wangen C, Bertzbach LD, Conradie AM, et al. Combinatorial drug treatments reveal promising anticytomegaloviral profiles for clinically relevant pharmaceutical kinase inhibitors (PKIs). Int J Mol Sci. 2021;22(2):575.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3303_CR16","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/pharmaceutics16091238","volume":"16","author":"D Obergf\u00e4ll","year":"2024","unstructured":"Obergf\u00e4ll D, Wiebusch K, Markus W, Mona S, Malena Barillas D, Jintawee K, et al. Cyclin-dependent kinase 8 represents a positive regulator of cytomegalovirus replication and a novel host target for antiviral strategies. Pharmaceutics. 2024;16(9):1238.","journal-title":"Pharmaceutics"},{"key":"3303_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04534-14","author":"C Hutterer","year":"2015","unstructured":"Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittr\u00e4ger I, Bahsi H, et al. A novel CDK7 inhibitor of the pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations. Antimicrob Agents Chemother. 2015. https:\/\/doi.org\/10.1128\/AAC.04534-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"3303_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052493","author":"M Wild","year":"2022","unstructured":"Wild M, Hahn F, Br\u00fcckner N, Sch\u00fctz M, Wangen C, Wagner S, et al. Cyclin-dependent kinases (CDKs) and the human cytomegalovirus-encoded CDK ortholog pUL97 represent highly attractive targets for synergistic drug combinations. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23052493.","journal-title":"Int J Mol Sci"},{"issue":"32","key":"3303_CR19","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346.","journal-title":"J Clin Oncol"},{"key":"3303_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tbcr-21-36","volume":"3","author":"L Yang","year":"2022","unstructured":"Yang L, Chen Y, Wang N, Han W. A narrative review of the clinical development of CDK4\/6 inhibitor abemaciclib in breast cancer. Transl Breast Cancer Res. 2022;3:4.","journal-title":"Transl Breast Cancer Res"},{"key":"3303_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2023.199200","volume":"335","author":"M Sch\u00fctz","year":"2023","unstructured":"Sch\u00fctz M, Wangen C, Sommerer M, K\u00f6gler M, Eickhoff J, Degenhart C, et al. Cytomegalovirus cyclin-dependent kinase ortholog vCDK\/pUL97 undergoes regulatory interaction with human cyclin H and CDK7 to codetermine viral replication efficiency. Virus Res. 2023;335:199200.","journal-title":"Virus Res"},{"issue":"12","key":"3303_CR22","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1038\/s41564-019-0557-8","volume":"4","author":"R Businger","year":"2019","unstructured":"Businger R, Deutschmann J, Gruska I, Milbradt J, Wiebusch L, Gramberg T, et al. Human cytomegalovirus overcomes SAMHD1 restriction in macrophages via pUL97. Nat Microbiol. 2019;4(12):2260\u201372.","journal-title":"Nat Microbiol"},{"issue":"10","key":"3303_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph18101560","volume":"18","author":"D Obergf\u00e4ll","year":"2025","unstructured":"Obergf\u00e4ll D, Hahn F, Kicuntod J, Wangen C, K\u00f6gler M, Wagner S, et al. New assay systems to characterize the broad-spectrum antiherpesviral and non-herpesviral activity of cyclin-dependent kinase (CDK) 8 inhibitors. Pharmaceuticals (Basel). 2025;18(10):1560.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"3303_CR24","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1128\/JVI.73.5.4110-4119.1999","volume":"73","author":"G Elliott","year":"1999","unstructured":"Elliott G, O\u2019Hare P. Live-cell analysis of a green fluorescent protein-tagged herpes simplex virus infection. J Virol. 1999;73(5):4110\u20139.","journal-title":"J Virol"},{"key":"3303_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1588-1597.2000","author":"M Marschall","year":"2000","unstructured":"Marschall M, Freitag M, Weiler S, Sorg G, Stamminger T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob Agents Chemother. 2000. https:\/\/doi.org\/10.1128\/AAC.44.6.1588-1597.2000.","journal-title":"Antimicrob Agents Chemother"},{"key":"3303_CR26","doi-asserted-by":"publisher","DOI":"10.4149\/av_2019_411","author":"K Briestensk\u00e1","year":"2019","unstructured":"Briestensk\u00e1 K, \u0160am\u0161ulov\u00e1 V, Pol\u00e1kov\u00e1 M, Mistr\u00edkov\u00e1 J. Recombinant luciferase-expressing murine gammaherpesvirus 68 as a tool for rapid antiviral screening. Acta Virol. 2019. https:\/\/doi.org\/10.4149\/av_2019_411.","journal-title":"Acta Virol"},{"key":"3303_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/v12121394","author":"F Hahn","year":"2020","unstructured":"Hahn F, Wangen C, H\u00e4ge S, Peter AS, Dobler G, Hurst B, et al. IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro. Viruses. 2020. https:\/\/doi.org\/10.3390\/v12121394.","journal-title":"Viruses"},{"issue":"1","key":"3303_CR28","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1080\/21505594.2021.1982373","volume":"12","author":"S Zhu","year":"2021","unstructured":"Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670\u2013702.","journal-title":"Virulence"},{"issue":"2","key":"3303_CR29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.4437","volume":"235","author":"P Griffiths","year":"2015","unstructured":"Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288\u201397.","journal-title":"J Pathol"},{"issue":"6","key":"3303_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189218","volume":"1879","author":"M Alsaadawe","year":"2024","unstructured":"Alsaadawe M, Radman BA, Long J, Alsaadawi M, Fang W, Lyu X. Epstein Barr virus: a cellular hijacker in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(6):189218.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"3303_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106168","author":"J Tillmanns","year":"2025","unstructured":"Tillmanns J, Battisti V, Kicuntod J, Hahn F, Obergf\u00e4ll D, Geiger P, et al. The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: pharmacophore-based identification of NEC-specific inhibitors. Antivir Res. 2025. https:\/\/doi.org\/10.1016\/j.antiviral.2025.106168.","journal-title":"Antivir Res"},{"key":"3303_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13080645","author":"J Tillmanns","year":"2024","unstructured":"Tillmanns J, Kicuntod J, Ehring A, Elbasani E, Borst EM, Obergf\u00e4ll D, et al. Establishment of a luciferase-based reporter system to study aspects of human cytomegalovirus infection, replication characteristics, and antiviral drug efficacy. Pathogens. 2024. https:\/\/doi.org\/10.3390\/pathogens13080645.","journal-title":"Pathogens"},{"key":"3303_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020158","author":"D Yu","year":"2024","unstructured":"Yu D, Wagner S, Sch\u00fctz M, Jeon Y, Seo M, Kim J, et al. An antiherpesviral host-directed strategy based on CDK7 covalently binding drugs: target-selective, picomolar-dose, cross-virus reactivity. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16020158.","journal-title":"Pharmaceutics"},{"key":"3303_CR34","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001370","author":"M Marschall","year":"2020","unstructured":"Marschall M, Strojan H, Kiener R, Wangen C, Sonntag E, M\u00fcller R, et al. Differential upregulation of host cell protein kinases by the replication of \u03b1-, \u03b2- and \u03b3-herpesviruses provides a signature of virus-specific signalling. J Gen Virol. 2020. https:\/\/doi.org\/10.1099\/jgv.0.001370.","journal-title":"J Gen Virol"},{"key":"3303_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","volume":"163","author":"RF Chemaly","year":"2019","unstructured":"Chemaly RF, Hill JA, Voigt S, Peggs KS. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antivir Res. 2019;163:50\u20138.","journal-title":"Antivir Res"},{"key":"3303_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081162","author":"J Tillmanns","year":"2023","unstructured":"Tillmanns J, H\u00e4ge S, Borst EM, Wardin J, Eickhoff J, Klebl B, et al. Assessment of covalently binding warhead compounds in the validation of the cytomegalovirus nuclear egress complex as an antiviral target. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12081162.","journal-title":"Cells"},{"issue":"6","key":"3303_CR37","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1128\/AAC.00238-15","volume":"59","author":"GD Tylden","year":"2015","unstructured":"Tylden GD, Hirsch HH, Rinaldo CH. Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells. Antimicrob Agents Chemother. 2015;59(6):3306\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3303_CR38","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1128\/AAC.48.10.3918-3927.2004","volume":"48","author":"DL Evers","year":"2004","unstructured":"Evers DL, Komazin G, Ptak RG, Shin D, Emmer BT, Townsend LB, et al. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother. 2004;48(10):3918\u201327.","journal-title":"Antimicrob Agents Chemother"},{"key":"3303_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(90)90001-N","author":"MN Prichard","year":"1990","unstructured":"Prichard MN, Shipman C. A three-dimensional model to analyze drug-drug interactions. Antivir Res. 1990. https:\/\/doi.org\/10.1016\/0166-3542(90)90001-N.","journal-title":"Antivir Res"},{"issue":"2","key":"3303_CR40","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","volume":"25","author":"FM Marty","year":"2019","unstructured":"Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369\u201381.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-026-03303-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-026-03303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:03:12Z","timestamp":1791486192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12985-026-03303-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3303"],"URL":"https:\/\/doi.org\/10.1186\/s12985-026-03303-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10256904\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"5 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The correct supplementary material has been replaced.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No experiments with animals or investigation of human probands was contained in this work, and no ethics approval or consent was required. All experiments with infectious agents were in line with relevant rules and regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have reviewed and approved the manuscript and consent to publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"219"}}